Table 3.
Haematological data before and after 8 weeks of intravesical chemotherapy
| Group | Time | WBC (109/l) | Hb (g l−1) | PLT (109/l) |
|---|---|---|---|---|
| Pre | 5.1 | 12.9 | 233 | |
| 1 | (4.5–6.0) | (11.0–13.9) | (217–250) | |
| Post | 6.7 | 13.7 | 228 | |
| (5.7–9.9) | (13.4–14.2) | (201–270) | ||
| Pre | 7.5 | 15.0 | 234 | |
| 2 | (6.6–11.2) | (14.4–15.9) | (221–239) | |
| Post | 6.8 | 14 | 247 | |
| (6.4–7.0) | (13.5–15.4) | (144–258) | ||
| Pre | 7.9 | 13.6 | 226 | |
| 3 | (5.7–8.8) | (11.5–15.7) | (188–261) | |
| Post | 8.0 | 14.1 | 271 | |
| (6.9–11.1) | (11.3–15) | (231–328) | ||
| Pre | 6.5 | 14 | 251 | |
| 4 | (5.6–9.1) | (13–15) | (152–260) | |
| Post | 6.7 | 13.9 | 248 | |
| (6.4–7.1) | (11–15) | (220–260) |
Data are expressed as the median (interquartile range). Group 1 patients were given MMC (20 mg) combined with hyperthermia. Group 2 patients were given MMC alone at the same dose as group 1. Group 3 patients were given MMC (40 mg) combined with hyperthermia. Group 4 patients were given ICT alone at the same dosage as Group 3. Groups 1, 2 and 4 underwent the first treatment session within 21–40 days after a complete TUR of tumours, while group 3 patients were treated by leaving their tumour intact as a debulking approach for a bladder sparing purposes.